Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.45

€1.45

2.690%
0.038
2.690%
-
 
18.04.24 / Frankfurt WKN: 913048 / Symbol: TRGNF / Name: Transgene / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Transgene

sharewise wants to provide you with the best news and tools for Transgene, so we directly link to the best financial data sources.

News

Transgene Announces Upcoming Investor Meetings: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Announces Upcoming Investor Meetings


Regulatory News:



TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below.



Transgene will meet

Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy


Regulatory News:



Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the

Transgene Reports Business Update and Q3 2023 Financial Position: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Reports Business Update and Q3 2023 Financial Position


Regulatory News:



Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update and its